Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 94Biopsy 60pembrolizumab 58Carboplatin 57Cisplatin 51Nivolumab 47Cyclophosphamide 40Radiotherapy 39Paclitaxel 37Gemcitabine 34Dexamethasone 34Bevacizumab 31Radiation 30atezolizumab 29Pemetrexed 28venetoclax 25olaparib 25Etoposide 25X-Rays 24Prednisone 23Immunoglobulin G 23Doxorubicin 23Disulfides 23Vincristine 22Lenalidomide 22Leucovorin 21Ipilimumab 21durvalumab 20Taxes 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × itacitinib × 30 days × Clear all
NCT05364762 2026-06-03

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

City of Hope Medical Center

Phase 2 Active not recruiting
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡